TinaEvansWoodMD

PubMed

• 76 citations
  CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alon...
  E. G. Chiorean, D. D. Von Hoff, Michele Reni, Francis P. Arena, J. R. Infante, Venu Bathini, T. E. Wood, Paul N. Mainwaring, R. T. Muldoon, Philip Clingan, Volker Kunz...> ;Annals of Oncology. 2016 Apr 1
• 7 citations
  Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
  Andrew M. McDonald, Caleb Dulaney, Javier López-Araujo, James Posey, Kimberly S. Keene, John D. Christein, Martin J. Heslin, T. E. Wood, Rojymon Jacob> ;Journal of Gastrointestinal Cancer. 2015 Mar 18
• By the Pricking of My Thumbs, Something Wicked This Way Comes: Sporadic Cancers Versus Eponymous Hereditary Cancer Predisposition Syndromes
  Christos Vaklavas, John R Ross, Lisle Nabell, Andres Forero, Martin J. Heslin, T. E. Wood> ;Journal of the National Comprehensive Cancer Network. 2012 Jan 1
• 811 citations
  Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
  Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Daniel A. Laheru, Lon Smith, T. E. Wood, Ronald L. Korn, Neil P. Desai, Vuong Trieu, Jose Iglesias, Hui Zhan...> ;Journal of Clinical Oncology. 2011 Dec 1
• 28 citations
  A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advance...
  Juan Pablo Arnoletti, Andrey Frolov, M. A. Eloubeidi, Kimberly S. Keene, James Posey, T. E. Wood, Edward W Greeno, Nirag Jhala, Shyam Varadarajulu, S. Russo, John D. C...> ;Cancer Chemotherapy and Pharmacology. 2011 Apr 1
• 114 citations
  Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).
  Andres Forero-Torres, Jatin J. Shah, T. E. Wood, James Posey, Ronda Carlisle, Catherine Copigneaux, Feng Roger Luo, Slawomir Wojtowicz-Praga, I. Percent, Mansoor N. Saleh> ;Cancer Biotherapy & Radiopharmaceuticals. 2010 Feb 28
• SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study.
  Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, Korn R, Desai N, Iglesias J, Hidalgo M> ;J. Clin. Oncol.. 2009-05-20
• A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas.
  Saleh MN, Percent I, Wood TE, Posey J, Shah J, Carlisle R, Wojtowicz-Praga S, Forero-Torres A> ;J. Clin. Oncol.. 2008-05-20
• Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer.
  Drengler RL, Smith LS, Wood TE, Borad MJ, Ramanathan RK, Laheru DA, Hidalgo M, Von Hoff DD> ;J. Clin. Oncol.. 2008-05-20
• Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancers: Acute toxicity profile and avoidance of a treatment break.
  Nordal RA, Wood TE, Posey JA> ;J. Clin. Oncol.. 2008-05-20
• SPARC and CA19-9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine.
  Smith LS, Drengler RL, Wood TE, Laheru DA, Hidalgo M, Borad MJ, Trieu V, Knauer D, Desai N, Von Hoff DD> ;J. Clin. Oncol.. 2008-05-20
• 31 citations
  Peripheral neuropathy associated with capecitabine.
  M. Wasif Saif, T. E. Wood, Philip J. McGee, Robert B. Diasio> ;Anti-Cancer Drugs. 2004 Sep 1
• Join now to see all